它的部分经费由吡格列酮的制造商武田制药提供。
It was financed in part by Takeda Pharmaceuticals, maker of pioglitazone.
目的：合成盐酸吡格列酮。
这种情况与吡格列酮不同。
吡格列酮增加严重的心衰，虽然死亡率没有增加。
Serious heart failure is increased by pioglitazone, although without an associated increase in mortality.
吡格列酮明显倾向于心血管获益方面或者非常接近。
Pioglitazone clearly has fallen on the side of cardiovascular benefits or very close.
吡格列酮与糖尿病患者膀胱癌和其他常见癌症的风险。
OBJECTIVE: To examine whether pioglitazone use for diabetes is associated with risk of bladder and 10 additional cancers.
吡格列酮与糖尿病患者膀胱癌和其他常见癌症的风险。
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
表2列举了吡格列酮及对照组共19项试验的临床结果。
TABLE 2 lists the clinical outcome measures in the pioglitazone and control groups of the 19 individual trials.
但是，在一些次要目标方面，吡格列酮明显优于安慰剂。
There was no benefit of pioglitazone over placebo for the primary outcome;
有关罗格列酮的一些负面新闻是否会对吡格列酮有影响？
Has some of the bad press and issues with rosiglitazone unfairly affected pioglitazone?
《国际糖尿病》：吡格列酮对血脂的作用是否优于罗格列酮？
International Diabetes: Does pioglitazone have more favorable effects on serum lipids than rosiglitazone?
当你观察吡格列酮复合的荟萃分析数据，它倾向于好的方面。
When you look at the composite meta-analysis data for pioglitazone, it falls on the good side.
目的建立检测中药降糖制剂中非法掺入的吡格列酮专属性方法。
OBJECTIVE to develop a specific method for the identification of pioglitazone illegally added into traditional Chinese medicine antidiabetic preparations.
然后，就在几个月前，FDA就吡格列酮可能的膀胱癌发出警告；
Then, just several months ago, the FDA put out warning about possible bladder cancer with pioglitazone;
结论吡格列酮、非诺贝特对大鼠能量代谢及体脂分布的影响不同。
Conclusion Pioglitazone and fenofibrate have different influences on energy homeostasis and body fat distribution in rats.
目的观察吡格列酮对2型糖尿病患者胰岛素敏感性和脂代谢的影响。
Objective Observe the effect of pioglitazone on insulin sensitivity and lipid metabolism in type 2 Diabetes Mellitus Patients.
这些早期的结果显示吡格列酮应用与膀胱癌风险之间没有总体的联系。
These early results showed no overall association between Actos exposure and risk of bladder cancer.
我个人的观点是吡格列酮应当在市场上保留，只用应用时多点儿谨慎。
My personal view is that pioglitazone should stay on the market and just be used a little more carefully.
目的：观察吡格列酮联用格列齐特缓释片治疗2型糖尿病的临床疗效。
Objective: To study the clinical effects of pioglitazone combined with glipizide on type 2 diabetes therapy.
目的观察吡格列酮对冠心病合并糖耐量异常患者冠脉支架内再狭窄的影响。
Objective to observe the effects of pioglitazone on stent restenosis in coronary heart disease patients with impaired glucose tolerance.
结论：在不同的糖尿病人中，吡格列酮明显降低死亡，心肌梗塞，和中风。
CONCLUSIONS: Pioglitazone is associated with a significantly lower risk of death, myocardial infarction, or stroke among a diverse population of patients with diabetes.
一半组员6个月期间每天服用45毫克吡格列酮，而剩下一半为安慰剂治疗。
About half of the group was given 45 milligrams of pioglitazone daily for six months, while the other half received a placebo.
吡格列酮联用磺脲类、胰岛素或者二甲双胍用于8项试验(8501个病人)。
Pioglitazone was tested in combination with a sulfonylurea, insulin, or metformin in 8 trials (8501 patients).
与安慰剂组的14%相比，服用吡格列酮组肝脏的胰岛素敏感型改善了48%。
Insulin sensitivity in the liver improved by 48 percent in the pioglitazone group, compared to 14 percent in the placebo group.
目的观察吡格列酮治疗糖尿病前期患者血管内皮细胞功能的变化及其可能的机制。
Objective To study whether pioglitazone therapy ameliorates endothelial dysfunction in pre-diabetic patients and the mechanism of it.
该项研究在周四发表于《新英格兰医学杂志》。它的部分经费由吡格列酮的制造商武田制药提供。
The study was published on Thursday in The New England Journal of Medicine. It was financed in part by Takeda Pharmaceuticals, maker of pioglitazone.
吡格列酮还能显著减轻PAN诱导的足细胞凋亡和坏死，而恢复足细胞的分化功能。
Further, pioglitazone significantly decreased PAN-induced podocyte apoptosis and necrosis while restoring podocyte differentiation.
目的观察胰岛素或胰岛素加吡格列酮治疗磺脲类继发失效2型糖尿病的疗效和安全性。
Objective It is to observe the curative effect and safety of insulin or insulin combined with pioglitazone on type 2 diabetes with sulfonylurea secondum refractoriness.
结论R2很可能是胰岛素增敏剂吡格列酮改善肝脏胰岛素敏感性的重要作用机制之一。
Conclusions The increased expression of R2 mRNA may play a important role in pioglitazone-induced insulin sensitivity amelioration.
结论吡格列酮可明显减少早期糖尿病肾病患者的UAER，并有显著降低血糖的作用。
Conclusion Pioglitazone can obviously decrease UAER of patients with early DN, and have the function of lowering the blood sugar.
应用推荐